Abstract:Despite a generally better prognosis than high-grade glioma (HGG), recurrence and malignant progression are the main causes for the poor prognosis and difficulties in the treatment of low-grade glioma (LGG). It is of great importance to learn about the risk factors and underlying mechanisms of LGG recurrence and progression. In this study, the transcriptome characteristics of four groups, namely, normal brain tissue and recurrent LGG (rLGG), normal brain tissue and secondary glioblastoma (sGBM), primary LGG (pLGG) and rLGG, and pLGG and sGBM, were compared using Chinese Glioma Genome Atlas (CGGA) and Genotype-Tissue Expression Project (GTEx) databases. In this study, 296 downregulated and 396 upregulated differentially expressed genes (DEGs) with high consensus were screened out. Univariate Cox regression analysis of data from The Cancer Genome Atlas (TCGA) yielded 86 prognostically relevant DEGs; a prognostic prediction model based on five key genes (HOXA1, KIF18A, FAM133A, HGF, and MN1) was established using the least absolute shrinkage and selection operator (LASSO) regression dimensionality reduction and multivariate Cox regression analysis. LGG was divided into high- and low-risk groups using this prediction model. Gene Set Enrichment Analysis (GSEA) revealed that signaling pathway differences in the high- and low-risk groups were mainly seen in tumor immune regulation and DNA damage-related cell cycle checkpoints. Furthermore, the infiltration of immune cells in the high- and low-risk groups was analyzed, which indicated a stronger infiltration of immune cells in the high-risk group than that in the low-risk group, suggesting that an immune microenvironment more conducive to tumor growth emerged due to the interaction between tumor and immune cells. The tumor mutational burden and tumor methylation burden in the high- and low-risk groups were also analyzed, which indicated higher gene mutation burden and lower DNA methylation level in the high-risk group, suggesting that with the accumulation of genomic mutations and epigenetic changes, tumor cells continued to evolve and led to the progression of LGG to HGG. Finally, the value of potential therapeutic targets for the five key genes was analyzed, and findings demonstrated that KIF18A was the gene most likely to be a potential therapeutic target. In conclusion, the prediction model based on these five key genes can better identify the high- and low-risk groups of LGG and lay a solid foundation for evaluating the risk of LGG recurrence and malignant progression.

COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma

COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas

Comprehensive Analysis of CD163 As a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.

Role of COL6A2 in malignant progression and temozolomide resistance of glioma

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Predictive Value of Focal Adhesion-Related Genes for Prognosis and Response to Immunotherapy in Glioma Patients

An Inflammatory Gene-Related Prognostic Risk Score Model for Prognosis and Immune Infiltration in Glioblastoma.

Molecular Insights and Prognosis Associated With RBM8A in Glioblastoma

SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma

High Expression of COL10A1 Is an Independent Predictive Poor Prognostic Biomarker and Associated with Immune Infiltration in Advanced Gastric Cancer Microenvironment

SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas

The Overexpression of GPX8 is Correlated with Poor Prognosis in GBM Patients.

Identification of SAA1 As a Prognostic Biomarker Associated with Immune Infiltration in Glioblastoma

Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation

Prognostic Value and Biological Function of Galectins in Malignant Glioma.

COL3A1 and SNAP91: Novel Glioblastoma Markers with Diagnostic and Prognostic Value

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

Clinical significance and potential mechanism of AEBP1 in glioblastoma

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis